SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report issued on Wednesday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other research firms have also issued reports on SABS. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research report on Wednesday. Craig Hallum began coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Trading Up 7.7 %

NASDAQ:SABS opened at $2.23 on Wednesday. SAB Biotherapeutics has a 52-week low of $2.01 and a 52-week high of $6.30. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $3.63 and its 200 day simple moving average is $3.13.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. On average, analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.